Oragenics, Inc. (OGEN) has entered into a material transfer agreement with Adjuvance Technologies Inc. for use of the adjuvant TQL1055 in the company's Terra CoV-2 vaccine against COVID-19. The agreement calls for TQL1055 to be used in pre-clinical animal studies.
Alan Joslyn, CEO of Oragenics, said: "Following our Type B Pre-IND meeting with the FDA, we were asked to conduct additional preclinical animal testing for inclusion in our IND filing. Access to TQL1055 will permit us to generate the data necessary to continue development of the vaccine along our currently expected timelines."
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.